CTRI vs SRE
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CTRI exhibits a strong deterministic health profile with a Piotroski F-Score of 8/9, indicating robust operational improvements. However, this fundamental health is completely decoupled from its market valuation, with the current price of $34.74 trading at a massive premium to both the Graham Number ($6.98) and Intrinsic Value ($7.38). Despite explosive YoY earnings growth, the company has missed analyst estimates in four consecutive quarters, and the current P/E of 138.96 is unsustainable. The stock is currently trading at its 52-week high while analyst target prices ($31.34) have already fallen below the current market price.
SRE shows bearish fundamentals based on deterministic rules. Financial strength is strong (F-Score 7/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
CTRI vs SRE: Head-to-Head Comparison
This page compares Centuri Holdings, Inc. (CTRI) and Sempra (SRE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.